Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding ...

AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence.

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the ...

The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim By David Jagielski – Jun 7, 2024 at 9:00AM ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on ...

With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.